Case Studies

Challenge A UK company had developed a novel system for urinary drainage that provided a number of benefits for patients and caregivers over current systems. It believed that CE marking would be...

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.

Challenge A UK public sector life sciences research institute focused on fundamental mammalian biology required an economic impact assessment of its science, as part of the evidence base accompanying...

Challenge A drug discovery company was in discussions with a big pharma about collaborating on a number of strategies that would deliver at least one quality clinical candidate. The pharma company...

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...

Challenge A research group at a leading research-intensive university had developed a qPCR diagnostic/ prognostic platform for patient stratification in autoimmune diseases which they believed could...

Challenge A company developing a novel wound care product was embarking on a significant clinical trial program. It was planning an investor exit in the next 24 months and therefore wanted to connect...

Challenge: Our diagnostics consultants were asked to develop an ex-US business development strategy and identify sources of non-dilutive finance for a well-backed, venture capital-funded diagnostics...

Challenge A private equity (PE) investor was looking for a partner to be retained as an observer on the board of a regenerative medicine/advanced wound-healing company.

Challenge A pharma company that specializes in discovering and developing antibiotics asked us to help expand the search for a development partner in some of its drug candidates.

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...